{"success":true,"data":{"pressRelease":{"id":"47299","rtpr_id":"nGNE62nWHR","ticker":"ARGX","exchange":"","all_tickers":["ARGX"],"title":"REG-argenx to Host Myositis R&D Webinar on June 23, 2026","author":"Globe Newswire","published_at":"2026-05-28T05:00:00.079Z","article_body":"May 28, 2026\n\nAmsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global\nimmunology company committed to improving the lives of people suffering from\nsevere autoimmune diseases, today announced it will host a webinar, titled\n“R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis” on\nTuesday, June 23, 2026, at 2:00pm ET.\n\nThe second webinar in the Company’s ‘mini’ series highlighting the\nargenx pipeline and research and development strategy will focus on myositis,\nan autoimmune rheumatic disease associated with progressive muscle damage and\nsignificant patient burden. The argenx team and leading clinicians treating\nmyositis will discuss emerging insights into disease biology, including the\nrole of autoantibodies as key disease drivers, as well as the ALKIVIA clinical\nprogram design and the clinical and commercial opportunity for efgartigimod.\n\nA webcast of the event can be accessed on the Investors section of the argenx\nwebsite at argenx.com/investors\n(https://www.globenewswire.com/Tracker?data=rl-udSMkDIplufk1Zv9F7XlZLZKjyECpwp3kSp6vnd4K1teKpkHPmo4Qtt79GhRsl6gnOP9Tu6XV2t4Qp5a4udOsUSB7peqybZSyczEXPW4=).\nA replay of the webcast will be available on the argenx website for\napproximately one year following the presentation.\n\nAbout argenx\nargenx is a global immunology company committed to improving the lives of\npeople suffering from severe autoimmune diseases. Partnering with leading\nacademic researchers through its Immunology Innovation Program (IIP), argenx\naims to translate immunology breakthroughs into a world-class portfolio of\nnovel antibody-based medicines. argenx developed and is commercializing the\nfirst approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad\npotential in multiple serious autoimmune diseases while advancing several\nearlier stage experimental medicines within its therapeutic franchises. For\nmore information, visit  www.argenx.com  and follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=aYmvYjBNgMzfRQEsUzXuT551h0_pvM86eIeyg1fwd1CiI6ftj2NSK2p8QXT_HULHtFghyq9JKq0VYsrK7h-_hPoWnyrmGG39aRhEeyOCkMhdxdoJ4dZhXKdjVh-vGPcqOxr7-8FFGmlrd6yyp011gKWwWRmS0VIxJuOYZTVNlDjVDImUVRTV40rAkWNHUjHZAnwifJ8jzd4K4iw62Km9ocpx_7Ne6VcXLKxfgCeUooBBlMBJBppE8_zRx3c1H8HPmj9Y2Z2mSF0urYrsjNpcL46f202Fg4gu2yJ0KxtcMSK0jEL4hnH3YVhaXrs0R4y3MkRSxtwcUf-k2A-T8iiSboDn6QUox1wiIzfXDdqo3Sc4ZGne1_mtwgrF_-XLTVXQTmVS2yDY66BjYFXNV0XSPVz__-ZCOIUzGQtb-1x8XBSCVKAA10J5dK-9VrijOaaluisAhuXiEcjLO1VPmQFu4wPXrcMgR4NowISkaCx5hNK6NyeQnCBwI7N8qt54JNw8ceupPd1ND8OhOaaAepnmjbQybWQzNDD7HKsRJHqiVvCV1d1WRMYfHCnIT5ic9g5mDskZhzNn2iBlxDXdKH7oSXzPMaWAjC5n3SMWV4VD7xxLi2irhgsIGcj0dAzTfkOdEN26rfIQIqXwqx5Wq7R7PwnBv_nIB94826QTwjDjJDEEPI7GVSFrorTYGjpNET_Mu8WB-Z8SlhM0Tk0TwhJuxUc85whg1-FMilXJdX2gC3fSbYb7LKs_7_NtwjwIUb5fTYYN51YTTIoF_R81tToy1ofGZqHJuh7lJnfGC3VCI5zR76jmsu3tu7Z3ObE0bJE3AO9ex4OqDvfKSX_jU2lJZBSCSEjP8dPEAK7VaBSxttMxrKjQBhXKhphz89U5s_j1GImKIqlLaGKaGTVWSBhBMw==), Instagram\n(https://www.globenewswire.com/Tracker?data=_gq4GcGIqbDPxw1BIBGppR1pwd3Hco0MW_DpkesZkLgfgAxY9V0SaPnuiXjOlN_fwBAMOF6d-h-MLztJ27Z8WJlsmzfxzIDYbPg9c4inIsxO19rJy8Cq_0n3mBoyz2xootqwxnAf_CrHxv1unz7Zm_RhMB0kt6YpaYuSw43fFNYbbpGwypS7nJF88yHoZMyxxM-faeUsxy-xVFCzgC-DLexKpXISnnxgHEKftRnjqrTK6hgWU9SyPTyeumH-kfFJ4NULg1HqBmuMo01tKXxbpqK1HluMALUY6909dCW9jWH08M4ieyVErgZ3YrxQ2t_KD-leg0DqLY3Pah4STTufGdG-GoGI8PcLnpHwOj1EyiLCMD9P0MMuv_aI3r5qWCYxT6C5cRDXoZFtQr5rTt4qkNNu-u_jZBSgcwra0Bi_ZDYTl1UqlQAKD4un47eQPV4RibqHijW6p-sGu22bm3K6_qlzbHKnFC--QBmAgTyESEHHdKYTsjfrqZTT8Rl4owvrlE7pRgnjpc7rjetcKbdHrROsFDCsVtDXCo-LjsYXTFEi3H6UMD4rA6R36-v5zRy0le1KB54nJfBVqV8UZRSjFIDyb4LVvgddO5dQuFh_XwMKx0j2a5IBrqGopICVWjyzXZAlkbzctKnRKnyLd057gVpj84CKd9DgkWBsHATsTTNMaPijXRXSg_E5Cnu8E0DBVgCATN_-o5NU9XJuu8NiRE_76V4xUcfXk1I6w-HXssC0exuba8ZvIumjVhM_JIpLvNhj5C3_7bYc2-bOR1IlG41I0zVlixbygGddpEq8MhX1AzDJUr63oMcfP32WuHBpBV2gpoPbMGpXNbOK36G4eKzOc9e5NLOhXMKhdMCdpedT_5NhoAy--IgmVoPaAy7q44jpHlnPY-Qa358hs6MnZQ==), Facebook\n(https://www.globenewswire.com/Tracker?data=G61ijtzcRleqwEr3h7X5-v0hQq-vlGDBax3-irNqTW2WXATa9nx_7FDLns9U1ZfVL_t05PyaS43rOkmxAFoEkGVGgw5KRP8issXD19NvA0lbjQNABcSTdXqf1MnrP0RhzxsQ8JKbkd625rKqfNmR7kYCATdmdKQqdCOHMoUeM9pn21iWOP8Op2CqA-Ij2KF-qfOJ1nEdpAf_lZrBu42BWdyjMLAxymVmvSpECHwW7yq5x4wU3r9szpKrrJghVWCKQtfK9rIQt5I1KqW_Nb-ZImixLbUcKAvk6hvDgo1EmRs3-OuNlus3o8gL-huufuhJNh5qEicd_zjFMwaMLW995j0fEPUX2Rvi8KXX9s2my6gUlU77MSFW9KRHFrnSI0ARxuPO3fPE0BYXI6YT9xB7iYXLbr69jDJaU2r8PYraoDBRUrNsTMWC8UCmlx-k7hQvlpSxXsKiV-lhpswirtcDME5a-gKoofK9zcgrAWgLoxtB66RLnnaYL1SiuXD_Yo2tao9hC50ICroIH_X8w7McPq7Rr1UUV2D_n2_0pmlOUe-gNC983gxP03_5SjPbz09to9PeEAoBn3xo-gCLXYo9_1wEOrPm71H16VfsZnzWldNZZ-ROBmxuRjATAdatrzoIL9gaPtmmoz3cmjWCZjXZdlPxCJX1Tkblu44HK3iwM2y7a4ndbXsqDv_t7nwe3BP1279JueXybOzCFG-UGsOQ_Nh1ooIXbvnGcRvN_IHnRUJPgW3YDET-oOxfmd8ZQuFjJ1hA04r8CbF7W5VvscN8A4FGdqe7WOuxEEUQNwx5XRNNkqA0s9Eh5Rbpn3BYDr0jh8pfulkHU-o47QiJX4506Xdip8ttHzL8qqXk0mXL6qAl5j5_LUz8XzhPg9zhKyCFLMpPm-vTpQGAzDWWaXaV4Q==),\nand YouTube\n(https://www.globenewswire.com/Tracker?data=lM6QkyaD-wmS1fgz6dly3APkOgbeJJuIpCLxavjobIY3PzE2Qff3E_bOBi3vFBe6sKWOCBfQ4VzfOes0ArReH3ZZMdK5ZCGC2KCHYStusMYZsXpHdpE9uQSFTcVy6oqhCrjYI-snPQUDndIsGy0NSxcFBpIKpanYOCfTzS6QLc0vDgRA2hLDu0KmZCZUKI55DT1rv1bkSPbzAjjcNzWPdiw5MXVy1sC2OeUH2bv7KNWvVainlidckd5CxefV7cT_HCQtZRtSDy1wbm7fUA4gMlLLMjq1JEB264LQfBPansJ1H3zoVMxsFGBBI0FEPyeTYCfv1SqyDYBAfn4IiyF8tSWw08yYiOb1Z7eEJANyTRqGVAsO9TjzC_RPjfL9SZoJqb3dDfaU3pKJqShzETHpqHwSLwRL_u6tRVSSgUYxqioaPfawjkhL337i4WFOr0RL5o6OWzCN1_vEm1k-qocWoEmpmD4SEqmFFxN2UbW8ynUbrHuU9rEDlNa497uEJb3Nr3TuQM_ItlrQjmX5K8UvSIyiEOzo3KWLwbW75gaVHA6-AGZbDU6WiypxMrydw-LVCZWk_qvnyKMGMYPKu9IGSpD7pu7OIVUtIUvR-Wpq6UUterr-Ip1ihDGgd9ir5c7oITnT9xmB3tvde7sC1TR-s5bQl6f4QMUiI8EqpfF-eWLEtOlTu3wxaaCSq-Wm4MjEOgLx26bbaJPlPCifA0PJ39V3uopwDh4yYYRONjd1s0f2_AMimKtxe1S_7lYSEeo4QxzqboAEGJLBOyAM6_E3NrXxZ9EL6jGLGhOxll0Tyw3BbLsIrYJUiyAc_wHO38-W_g1LOhonnwrYcCQdF0m8yFSN-luxigsE5er7WqWIbj0dUmoSrXWgTB0kACABGGrVxP33on9BJWdA9aXqBx9QoQ==).\n\nContacts\n\nMedia:\n\nColin McBean\ncmcbean@argenx.com\n\nInvestors:\n\nAlexandra Roy \naroy@argenx.com","article_body_html":"","raw_payload":{"data":{"id":"nGNE62nWHR","title":"REG-argenx to Host Myositis R&D Webinar on June 23, 2026","author":"Globe Newswire","ticker":"ARGX","created":"2026-05-28T05:00:00.079Z","tickers":["ARGX"],"exchange":"","article_body":"May 28, 2026\n\nAmsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global\nimmunology company committed to improving the lives of people suffering from\nsevere autoimmune diseases, today announced it will host a webinar, titled\n“R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis” on\nTuesday, June 23, 2026, at 2:00pm ET.\n\nThe second webinar in the Company’s ‘mini’ series highlighting the\nargenx pipeline and research and development strategy will focus on myositis,\nan autoimmune rheumatic disease associated with progressive muscle damage and\nsignificant patient burden. The argenx team and leading clinicians treating\nmyositis will discuss emerging insights into disease biology, including the\nrole of autoantibodies as key disease drivers, as well as the ALKIVIA clinical\nprogram design and the clinical and commercial opportunity for efgartigimod.\n\nA webcast of the event can be accessed on the Investors section of the argenx\nwebsite at argenx.com/investors\n(https://www.globenewswire.com/Tracker?data=rl-udSMkDIplufk1Zv9F7XlZLZKjyECpwp3kSp6vnd4K1teKpkHPmo4Qtt79GhRsl6gnOP9Tu6XV2t4Qp5a4udOsUSB7peqybZSyczEXPW4=).\nA replay of the webcast will be available on the argenx website for\napproximately one year following the presentation.\n\nAbout argenx\nargenx is a global immunology company committed to improving the lives of\npeople suffering from severe autoimmune diseases. Partnering with leading\nacademic researchers through its Immunology Innovation Program (IIP), argenx\naims to translate immunology breakthroughs into a world-class portfolio of\nnovel antibody-based medicines. argenx developed and is commercializing the\nfirst approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad\npotential in multiple serious autoimmune diseases while advancing several\nearlier stage experimental medicines within its therapeutic franchises. For\nmore information, visit  www.argenx.com  and follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=aYmvYjBNgMzfRQEsUzXuT551h0_pvM86eIeyg1fwd1CiI6ftj2NSK2p8QXT_HULHtFghyq9JKq0VYsrK7h-_hPoWnyrmGG39aRhEeyOCkMhdxdoJ4dZhXKdjVh-vGPcqOxr7-8FFGmlrd6yyp011gKWwWRmS0VIxJuOYZTVNlDjVDImUVRTV40rAkWNHUjHZAnwifJ8jzd4K4iw62Km9ocpx_7Ne6VcXLKxfgCeUooBBlMBJBppE8_zRx3c1H8HPmj9Y2Z2mSF0urYrsjNpcL46f202Fg4gu2yJ0KxtcMSK0jEL4hnH3YVhaXrs0R4y3MkRSxtwcUf-k2A-T8iiSboDn6QUox1wiIzfXDdqo3Sc4ZGne1_mtwgrF_-XLTVXQTmVS2yDY66BjYFXNV0XSPVz__-ZCOIUzGQtb-1x8XBSCVKAA10J5dK-9VrijOaaluisAhuXiEcjLO1VPmQFu4wPXrcMgR4NowISkaCx5hNK6NyeQnCBwI7N8qt54JNw8ceupPd1ND8OhOaaAepnmjbQybWQzNDD7HKsRJHqiVvCV1d1WRMYfHCnIT5ic9g5mDskZhzNn2iBlxDXdKH7oSXzPMaWAjC5n3SMWV4VD7xxLi2irhgsIGcj0dAzTfkOdEN26rfIQIqXwqx5Wq7R7PwnBv_nIB94826QTwjDjJDEEPI7GVSFrorTYGjpNET_Mu8WB-Z8SlhM0Tk0TwhJuxUc85whg1-FMilXJdX2gC3fSbYb7LKs_7_NtwjwIUb5fTYYN51YTTIoF_R81tToy1ofGZqHJuh7lJnfGC3VCI5zR76jmsu3tu7Z3ObE0bJE3AO9ex4OqDvfKSX_jU2lJZBSCSEjP8dPEAK7VaBSxttMxrKjQBhXKhphz89U5s_j1GImKIqlLaGKaGTVWSBhBMw==), Instagram\n(https://www.globenewswire.com/Tracker?data=_gq4GcGIqbDPxw1BIBGppR1pwd3Hco0MW_DpkesZkLgfgAxY9V0SaPnuiXjOlN_fwBAMOF6d-h-MLztJ27Z8WJlsmzfxzIDYbPg9c4inIsxO19rJy8Cq_0n3mBoyz2xootqwxnAf_CrHxv1unz7Zm_RhMB0kt6YpaYuSw43fFNYbbpGwypS7nJF88yHoZMyxxM-faeUsxy-xVFCzgC-DLexKpXISnnxgHEKftRnjqrTK6hgWU9SyPTyeumH-kfFJ4NULg1HqBmuMo01tKXxbpqK1HluMALUY6909dCW9jWH08M4ieyVErgZ3YrxQ2t_KD-leg0DqLY3Pah4STTufGdG-GoGI8PcLnpHwOj1EyiLCMD9P0MMuv_aI3r5qWCYxT6C5cRDXoZFtQr5rTt4qkNNu-u_jZBSgcwra0Bi_ZDYTl1UqlQAKD4un47eQPV4RibqHijW6p-sGu22bm3K6_qlzbHKnFC--QBmAgTyESEHHdKYTsjfrqZTT8Rl4owvrlE7pRgnjpc7rjetcKbdHrROsFDCsVtDXCo-LjsYXTFEi3H6UMD4rA6R36-v5zRy0le1KB54nJfBVqV8UZRSjFIDyb4LVvgddO5dQuFh_XwMKx0j2a5IBrqGopICVWjyzXZAlkbzctKnRKnyLd057gVpj84CKd9DgkWBsHATsTTNMaPijXRXSg_E5Cnu8E0DBVgCATN_-o5NU9XJuu8NiRE_76V4xUcfXk1I6w-HXssC0exuba8ZvIumjVhM_JIpLvNhj5C3_7bYc2-bOR1IlG41I0zVlixbygGddpEq8MhX1AzDJUr63oMcfP32WuHBpBV2gpoPbMGpXNbOK36G4eKzOc9e5NLOhXMKhdMCdpedT_5NhoAy--IgmVoPaAy7q44jpHlnPY-Qa358hs6MnZQ==), Facebook\n(https://www.globenewswire.com/Tracker?data=G61ijtzcRleqwEr3h7X5-v0hQq-vlGDBax3-irNqTW2WXATa9nx_7FDLns9U1ZfVL_t05PyaS43rOkmxAFoEkGVGgw5KRP8issXD19NvA0lbjQNABcSTdXqf1MnrP0RhzxsQ8JKbkd625rKqfNmR7kYCATdmdKQqdCOHMoUeM9pn21iWOP8Op2CqA-Ij2KF-qfOJ1nEdpAf_lZrBu42BWdyjMLAxymVmvSpECHwW7yq5x4wU3r9szpKrrJghVWCKQtfK9rIQt5I1KqW_Nb-ZImixLbUcKAvk6hvDgo1EmRs3-OuNlus3o8gL-huufuhJNh5qEicd_zjFMwaMLW995j0fEPUX2Rvi8KXX9s2my6gUlU77MSFW9KRHFrnSI0ARxuPO3fPE0BYXI6YT9xB7iYXLbr69jDJaU2r8PYraoDBRUrNsTMWC8UCmlx-k7hQvlpSxXsKiV-lhpswirtcDME5a-gKoofK9zcgrAWgLoxtB66RLnnaYL1SiuXD_Yo2tao9hC50ICroIH_X8w7McPq7Rr1UUV2D_n2_0pmlOUe-gNC983gxP03_5SjPbz09to9PeEAoBn3xo-gCLXYo9_1wEOrPm71H16VfsZnzWldNZZ-ROBmxuRjATAdatrzoIL9gaPtmmoz3cmjWCZjXZdlPxCJX1Tkblu44HK3iwM2y7a4ndbXsqDv_t7nwe3BP1279JueXybOzCFG-UGsOQ_Nh1ooIXbvnGcRvN_IHnRUJPgW3YDET-oOxfmd8ZQuFjJ1hA04r8CbF7W5VvscN8A4FGdqe7WOuxEEUQNwx5XRNNkqA0s9Eh5Rbpn3BYDr0jh8pfulkHU-o47QiJX4506Xdip8ttHzL8qqXk0mXL6qAl5j5_LUz8XzhPg9zhKyCFLMpPm-vTpQGAzDWWaXaV4Q==),\nand YouTube\n(https://www.globenewswire.com/Tracker?data=lM6QkyaD-wmS1fgz6dly3APkOgbeJJuIpCLxavjobIY3PzE2Qff3E_bOBi3vFBe6sKWOCBfQ4VzfOes0ArReH3ZZMdK5ZCGC2KCHYStusMYZsXpHdpE9uQSFTcVy6oqhCrjYI-snPQUDndIsGy0NSxcFBpIKpanYOCfTzS6QLc0vDgRA2hLDu0KmZCZUKI55DT1rv1bkSPbzAjjcNzWPdiw5MXVy1sC2OeUH2bv7KNWvVainlidckd5CxefV7cT_HCQtZRtSDy1wbm7fUA4gMlLLMjq1JEB264LQfBPansJ1H3zoVMxsFGBBI0FEPyeTYCfv1SqyDYBAfn4IiyF8tSWw08yYiOb1Z7eEJANyTRqGVAsO9TjzC_RPjfL9SZoJqb3dDfaU3pKJqShzETHpqHwSLwRL_u6tRVSSgUYxqioaPfawjkhL337i4WFOr0RL5o6OWzCN1_vEm1k-qocWoEmpmD4SEqmFFxN2UbW8ynUbrHuU9rEDlNa497uEJb3Nr3TuQM_ItlrQjmX5K8UvSIyiEOzo3KWLwbW75gaVHA6-AGZbDU6WiypxMrydw-LVCZWk_qvnyKMGMYPKu9IGSpD7pu7OIVUtIUvR-Wpq6UUterr-Ip1ihDGgd9ir5c7oITnT9xmB3tvde7sC1TR-s5bQl6f4QMUiI8EqpfF-eWLEtOlTu3wxaaCSq-Wm4MjEOgLx26bbaJPlPCifA0PJ39V3uopwDh4yYYRONjd1s0f2_AMimKtxe1S_7lYSEeo4QxzqboAEGJLBOyAM6_E3NrXxZ9EL6jGLGhOxll0Tyw3BbLsIrYJUiyAc_wHO38-W_g1LOhonnwrYcCQdF0m8yFSN-luxigsE5er7WqWIbj0dUmoSrXWgTB0kACABGGrVxP33on9BJWdA9aXqBx9QoQ==).\n\nContacts\n\nMedia:\n\nColin McBean\ncmcbean@argenx.com\n\nInvestors:\n\nAlexandra Roy \naroy@argenx.com"},"type":"article","timestamp":"2026-05-28T05:00:00.172735072Z","server_sent_at_ms":1779944400172},"received_at":"2026-05-28T05:00:00.242Z","source_url":null},"analysis":{"id":"36732","press_release_id":"47299","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"argenx will host an R&D webinar on June 23, 2026, titled 'R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis'.\n\nThe session is the second in a 'mini' series highlighting the company's pipeline and will focus on myositis, an autoimmune rheumatic disease.\n\nThe argenx team and leading clinicians will discuss disease biology, the ALKIVIA clinical program design, and the commercial opportunity for efgartigimod.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine IR webinar announcement; no new data to trade on."},"keyFigures":{},"quotedText":"R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis","namedEntities":{"people":[{"name":"Colin McBean","role":"Media Contact"},{"name":"Alexandra Roy","role":"Investor Relations Contact"}],"products":["ALKIVIA","efgartigimod"],"companies":[{"name":"argenx","ticker":"ARGX","relationship":"filer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is a routine announcement of an upcoming R&D webinar. It contains no new clinical data, regulatory updates, or financial figures. It is a standard investor relations activity with no immediate market-moving impact."},"tickerRelevance":{"others":[],"primary":"ARGX"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"ir_webinar","householdBrandBoost":0,"retailFavoriteBoost":0}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"argenx will host an R&D webinar on June 23, 2026, titled 'R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis'.\n\nThe session is the second in a 'mini' series highlighting the company's pipeline and will focus on myositis, an autoimmune rheumatic disease.\n\nThe argenx team and leading clinicians will discuss disease biology, the ALKIVIA clinical program design, and the commercial opportunity for efgartigimod.","key_figures":{},"named_entities":{"people":[{"name":"Colin McBean","role":"Media Contact"},{"name":"Alexandra Roy","role":"Investor Relations Contact"}],"products":["ALKIVIA","efgartigimod"],"companies":[{"name":"argenx","ticker":"ARGX","relationship":"filer"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-28T05:00:19.617Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"mid-cap","eventGravity":"ir_webinar","householdBrandBoost":0,"retailFavoriteBoost":0}},"durationMs":19549,"modelName":"george-droid-qwen-72b"}}